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 Abstract 
Context: Considering that bitter taste of drugs incorporated in orally disintegrating tablets 
(ODTs) can be the main reason for avoiding drug therapy, it is of the utmost importance to 
achieve successful taste-masking. The evaluation of taste-masking effectiveness is still a major 
challenge. 
Objective: The objective of this study was to mask bitter taste of the selected model drugs by 
drug particle coating with Eudragit
®
 E PO, as well as to evaluate taste-masking effectiveness of 
prepared ODTs using compendial dissolution testing, dissolution in the small-volume shake-
flask assembly and trained human taste panel.  
Materials and methods: Model drugs were coated in fluidized bed. Disintequik™ ODT was used 
as a novel co-processed excipient for ODT preparation. Selected formulations were investigated 
in vitro and in vivo using techniques for taste-masking assessment.  
Results and discussion: Significantly slower drug dissolution was observed from tablets with 
coated drug particles during the first three minutes of investigation. Results of in vivo taste-
masking assessment demonstrated significant improvement in drug bitterness suppression in 
formulations with coated drug. Strong correlation between the results of drug dissolution in the 
small-volume shake-flask assembly and in vivo evaluation data was established (R ≥ 0.970). 
Conclusion: Drug particle coating with Eudragit
®
 E PO can be a suitable approach for bitter 
taste-masking. Strong correlation between in vivo and in vitro results implicate that small-
volume dissolution method may be used as surrogate for human panel taste-masking assessment, 
in the case of physical taste-masking approach application.  
Keywords: taste-masking, small-volume shake-flask assembly, trained human taste panel, in 
vitro-in vivo correlation, drug particle coating  
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 Introduction 
Orally disintegrating tablets (ODTs) emerged as convenient alternative to conventional solid 
dosage forms. According to European Pharmacopoeia, ODTs should disintegrate in less than 3 
minutes into a suspension or solution in the oral cavity, without applying additional water
1
. 
Orally disintegrating dosage forms offer numerous advantages, such as: i) facilitated swallowing
2
 
and, thus, increased compliance in the pediatric and geriatric populations and possibility of use 
“anytime and anywhere”3, ii) faster achievement of desired therapeutic drug effect4 and iii) 
increase in the bioavailability of poorly soluble drugs
5,6
. One of their main drawbacks is the need 
for masking the taste of incorporated, bitter, highly soluble, active pharmaceutical ingredients 
(APIs). After ODT disintegration, highly soluble drugs will release, dissolve and interact with 
receptors of the taste buds, predominantly distributed over the surface of the tongue
7,8
. 
Considering that bitter taste of APIs can be the main reason for avoiding drug therapy, it is of the 
utmost importance to achieve successful taste-masking
9
. 
Different taste-masking approaches include: i) sensory (gustatory), ii) chemical and iii) physical 
approach. Sensory method is usually combined with more complex chemical or physical 
methods. It includes flavors or sweeteners addition
10-14
. The aim of physical and chemical 
approaches is to slow down dissolution of the unpleasant tasting drug in the oral cavity. Physical 
taste-masking approaches include granulation, extrusion or coating the drug with different 
polymers
10,14-17
; or preparation of microspheres by solvent evaporation method
18
. Coating in 
fluidized bed can be used for masking the unpleasant taste of drug
11,15,19
.
 
However, it is necessary 
to demonstrate that coating does not violate critical ODT characteristics, such as tablet hardness, 
disintegration time, as well as dissolution of the incorporated drug
20
. Generally, particles larger 
than 350 µm can lead to gritty taste in mouth, which can impact patient compliance
11
. In order to 
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 maintain the small particle size, direct drug particle coating can be applied. Guhmann and 
coworkers investigated effectiveness of drug particle coating, in the case of diclofenac, low 
solubility model substance
11
. In the present study, paracetamol and caffeine anhydrous were 
selected as highly soluble bitter drug substances, which could dissolve in the limited saliva 
volume, taking into consideration the reported aqueous solubility at 25° C of 14.3 mg/ml and 
21.9 mg/ml for paracetamol and caffeine anhydrous, respectively
21,22
. 
Despite the fact that numerous techniques for masking the taste of drug substances have been 
developed, the evaluation of taste-masking effectiveness is still a major challenge. Standardized 
guidance for the in vitro taste-masking assessment is lacking. Therefore, many authors attempt to 
develop specific methods, which are in correlation with the in vivo data
23
. There are several in 
vitro techniques used for evaluation of taste-masking effectiveness, such as: i) compendial 
dissolution testing
10,11,24,25
, ii) shake-flask method
26,27 
and iii) electronic taste-sensing 
systems
11,25,28,29
. Although application of electronic taste-sensing system recently gained in 
significance, there are still certain difficulties considering evaluation of taste-masked ODTs, 
such as sample preparation
23
.
 
Insoluble particles can cause damage of the taste-sensing system 
sensors
23
. Hence, before investigation ODTs should be dispersed in adequate medium and, 
filtrated immediately in order to remove insoluble particles and avoid ongoing drug dissolution. 
For proper evaluation, solutions in the volume range from 25 up to 100 ml have to be 
investigated
30
. Therefore, the crucial step is fast filtration of large solution volumes. There is a 
limitation related to establishment of the relationship between sensor responses and different 
drug concentration, in the case of neutral substances (such as paracetamol and caffeine)
30
. 
Trained human taste panel is still the gold standard in taste-masking effectiveness 
evaluation
15,23,28,29,31
, irrespective of being expensive and subject to ethical considerations and 
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 inter-subject variability
20
. Correlation between in vitro and in vivo methods for taste-masking 
evaluation is difficult to establish considering higher sensitivity of the proposed in vitro 
methods
28
.  
The aim of the present study was to mask bitter taste of the selected model drugs by drug particle 
coating, evaluate taste-masking effectiveness of prepared orally disintegrating tablets and 
establish correlation between in vitro and in vivo data. Eudragit
®
 E PO, amino methacrylate 
copolymer insoluble above pH 5, was used for particle coating
32
. Disintequik™ ODT, novel co-
processed excipient consisting of lactose monohydrate, spray-dried mannitol, crospovidone and 
dextrose monohydrate, was used as diluent for direct compression. Taste-masking effectiveness 
was evaluated in vitro and in vivo, using compendial dissolution testing, dissolution in small-
volume shake-flask assembly and trained human taste panel.  
Materials and methods 
Materials 
Paracetamol - PAR (Acros Organics, Geel, Belgium) and caffeine anhydrous - CA (BASF, 
Ludwigshafen, Germany) were used as model drugs; Eudragit
®
 E PO, (Evonik, Nordrhein-
Westfalen, Germany) was used as coating polymer; sodium lauryl sulfate (Ph. Eur. 8.0), stearic 
acid (Ph. Eur. 8.0), and talc (Ph. Eur. 8.0) were used, respectively, as wetting agent, plasticizer 
and glidant in the polymer dispersion; Disintequik™ ODT (Kerry, Beloit, WI USA), co-
processed excipient, was used for direct compression of ODTs; sodium stearyl fumarate (JRS 
Pharma, Rosenberg, Germany) was used as a lubricant; raspberry flavor was kindly gifted by 
Firmenich (Geneva, Switzerland); sodium chloride (Sigma–Aldrich Chemie GmbH, Steinheim, 
Germany), potassium phosphate monobasic (Sigma–Aldrich Chemie GmbH, Steinheim, 
Germany), disodium hydrogen phosphate (Ph. Eur. 8.0), and hydrochloric acid (Sigma–Aldrich 
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 Chemie GmbH, Steinheim, Germany) were used for preparation of simulated saliva. Commercial 
bottled water (Aqua viva
™, Knjaz Miloš, A.D. Aranđelovac, Serbia) was used for standard 
solutions preparation and mouth rinse for in vivo taste-masking assessment.  
Methods 
Preparation of Eudragit
®
 E PO aqueous dispersion 
Preparation of Eudragit
®
 E PO dispersion in distilled water was carried out in three steps: sodium 
lauryl sulfate was stirred in 70% of the total water amount for 5 min, using magnetic stirrer, 
heated at 50 °C; then, stearic acid and Eudragit
®
 E PO were added and the suspension was stirred 
for 1 h; talc was dispersed in the remaining water, using rotor–stator homogenizer (IKA Ultra-
Turrax
®
 T25 digital, IKA
®
-Werke GmbH, Staufen, Germany). Two suspensions were mixed 
together and stirred with Ultra-Turrax
®
 T25, for 15 min, reducing the speed of mixing over time 
(from 10 000 to 6 000 rpm). Suspension was heated to facilitate formation of the colloidal 
dispersion and to prevent foaming
33
. Proportion of solids in the coating dispersion was 12%. 
Eudragit
®
 E PO load was 30% relative to the amount of drug while the contents of sodium lauryl 
sulfate, talc and stearic acid, were, respectively, 10, 15 and 10% relative to the polymer weight.  
Fluidized bed coating 
Paracetamol and caffeine were sieved in order to remove fines and particles agglomerates. Drug 
particles fraction in the range from 125 to 355 µm was coated in Mycrolab fluid bed processor 
(OYSTAR Hüttlin, Schopfheim, Germany), in the top-spray configuration, using the 0.8 mm 
nozzle. Fluid bed processor was connected to a personal computer allowing the process 
parameters to be monitored and recorded. The batch size was 140 g. Processing chamber was 
preheated to 55-60 °C, whereupon drug powder was filled into the processing chamber and 
fluidized. Eudragit
®
 E PO aqueous dispersion was sprayed onto the fluidized particles, at feed 
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 rate of 2.2-4.3 g/min. The inlet air flow rate was 15-20 m
3
/h, and the inlet air temperature was set 
to 45 °C. The microclimate and spray air pressure were 0.5 and 0.8 bar, respectively. Filters were 
shaken for 0.2 s in alternating mode during the whole process.  
Characterization of coated particles 
Size distribution 
Size distribution of coated particles (sample size 100 g) was evaluated by sieve analysis using 
the vibrating shaker (Erweka AR400, Heusenstamm, Germany) and five standard sieves in the 
range 63-355 µm. The amount of material remained on each sieve was accurately weighted to 
determine the particle size distribution. 
Drug content 
Drug content was determined spectrophotometrically (Cary 50, Varian, Santa Clara, USA), after 
dispersion of 100 mg of coated particles in 100 ml of 0.1 M hydrochloric acid, using the shaker 
(KS 260 basic, IKA
®
-Werke GmbH, Staufen, Germany) at 400 rpm. Dispersion was filtered 
through a 0.45 µm Millipore filter (Millipore, Bedford, MA, UK), diluted and analyzed at 245 
nm in the case of PAR and 272 nm in the case of CA. Each sample was analyzed in triplicate and 
results are shown as the mean with standard deviation.   
Flowability 
Flowability of uncoated and coated drug particles was determined using Flow meter (Erweka 
GDT, Heusenstamm, Germany). Results are expressed as the mean value of three replicates. 
Moisture content 
Residual moisture content of the prepared coated particles was determined gravimetrically using 
a halogen moisture analyzer (Chyo IB-30, Sun Scientific Co Ltd, Japan).  
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 Scanning electron micrographs 
Morphology of uncoated and coated drug particles was examined using high-resolution desktop 
scanning electron microscope (Phenom G2 Pro, Phenom-World, Eindhoven, Netherlands). 
Coated particles were cut with a scalpel and a surface was de-dusted by compressed air to obtain 
a clear cross section. Samples were placed in the microscope holder and images were taken at a 
suitable magnification.  
Tablet preparation 
Orally disintegrating tablets were prepared by mixing appropriate amounts of drug with 
Disintequik™ ODT, sodium stearyl fumarate and flavor and compressed on a single-punch tablet 
press (EKO Korsch, Berlin, Germany), using flat faced punches with a diameter of 8 mm. All 
samples were compressed under the same compression force and filling volume. Tablet weight 
was set to 200 mg, while the drug content was 50 mg per tablet (25% of total tablet weight). 
Composition of the investigated samples (F1-F8) is presented in Table 1. Reference drug-free 
formulation consists of Disintequik™ ODT, sodium stearyl fumarate and coating dispersion 
components.  
Characterization of tablets 
Tensile strength 
Tablet hardness was evaluated using tablet hardness tester (Erweka TBH 125D, Heusenstamm, 
Germany). Tensile strength (T, MPa) was calculated using the formula devised by Fell and 
Newton
34
:  
T = (2×P)/(π×D×t)                 (1) 
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 Where P (N) is the force applied for tablet breaking, D (mm) is the tablet diameter and t (mm) is 
the tablet thickness. Thickness of the tablet was determined using caliper. Six tablets of each 
formulation were subjected to tensile strength determination.  
Friability 
Tablet friability was evaluated using friabilator (Erweka AR400, Heusenstamm, Germany) at 25 
rpm/min for 4 minutes. Ten tablets of each formulation were tested. Friability was reported as a 
loss in tablet weight (%).  
Disintegration testing 
In vitro ODT disintegration time was determined using the compendial disintegration apparatus 
(Erweka ZT52, Heusenstamm, Germany). 800 ml of simulated salivary fluid (SSF), pH 6.75, 
heated to 37 ± 0.5 °C, was used as immersion medium. SSF consists of 2.38 g disodium 
hydrogen phosphate, 0.19 g potassium phosphate monobasic and 8.00 g sodium chloride per liter 
of distilled water adjusted with hydrochloric acid to pH 6.75
35
. Six tablets from each sample 
were investigated and the values are reported as mean ± standard deviation.  
Dissolution testing 
Drug dissolution testing was performed using the standard rotating paddle apparatus, as well as 
the small-volume shake-flask assembly. Drug release studies for all the investigated samples 
(F1-F8) were carried out in 800 ml of degassed SSF using the rotating paddle apparatus (Erweka 
DT600, Heusenstamm, Germany) at 50 rpm and 37 ± 0.5 °C. Content of dissolved drug was 
measured in-situ, every 10 s up to complete tablet disintegration, using the UV fiber optic probe 
(Cary 50, Varian, Santa Clara, USA) operating at 270 nm in the case of PAR and 245 nm in the 
case of CA. Results are expressed as the mean value of six replicates. 
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 The selected ODT formulations containing uncoated drug and flavor (F2 and F6), or coated drug 
particles (F3 and F7) were investigated using the small-volume shake-flask assembly simulating 
drug dissolution in oral cavity. ODT samples were shaken in 10 ml of SSF, in 25-ml Erlenmeyer 
flask, on the laboratory shaker (KS 260 basic, IKA
®
-Werke GmbH, Staufen, Germany) at 50 
rpm, in order to simulate agitation in the oral cavity. In the predefined time points (10, 20, 30, 
45, 60, 90 and 120 s) samples were filtered through a 0.45 µm Millipore filter (Millipore, 
Bedford, MA) and the amount of drug dissolved was determined spectrophotometrically (Cary 
50, Varian, Santa Clara, USA). Results are expressed as the mean value of six replicates. 
In vivo taste-masking assessment 
In vivo taste-masking assessment was performed in a panel of ten healthy, non-smoking, trained, 
adult, human volunteers, of either sex. The ages of panelists were from 20-29. Prior to the in vivo 
study, volunteers were informed in detail on the purpose of the test and gave informed consent. 
The study was approved by the Ethics Committee of the Faculty of Pharmacy, University of 
Belgrade. In vivo study was conducted in three phases: i) determination of drug bitterness value, 
ii) training of panelists and iii) evaluation of taste-masking effectiveness. First phase was 
performed on Day 1 of the study, while the second and third phases were carried out on Day 2. 
The panelists were instructed to abstain from food and beverage intake for two hours before 
samples administration and during the study. 
Panelists were asked to taste five aqueous standard solutions of each model drug, by keeping 10 
ml of solution for 30 s in oral cavity. The range of concentrations used was 0.5-2.1 mg/ml for 
PAR and 0.1-0.3 mg/ml for CA, as determined in the preliminary trials. The washout period 
between each solution tasting was 10 min. After each sample tasting, volunteers rinsed the mouth 
with water and reported if the solution was bitter or not. Concentration of the most diluted drug 
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 solution, for which a bitter taste was reported at least by one of the panelists, was defined as the 
drug bitterness value
36
. 
Second phase of the study included volunteers training, in order to standardize their responses in 
the third phase
23
. According to preliminary trials and results from the first phase, five standard 
solutions of each drug were prepared (Table 2). After tasting 10 ml of each solution during 30 s, 
panelists were informed about numerical value and taste description of the tasted solution. 
Training was replicated. 
The third phase consisted of ODTs tasting with the aim to evaluate effectiveness of masking the 
drug bitterness. Panelists were asked to taste randomly ODT samples (samples F2, F3 containing 
PAR, and samples F6, F7 containing CA), as well as the reference drug-free formulation, and 
assign the bitterness score for each tablet after 10 s, 30 s, at the time of tablet disintegration and 
10 s after that. The ODT was placed on the tongue and panelists moved the tablet against the 
upper part of the mouth, to produce tumbling. The moment when no lumps remained in oral 
cavity, was considered as point of tablet disintegration
37
. In vivo disintegration time was 
recorded. After tasting each tablet, the mouth was rinsed with water, without swallowing the 
disintegrated material, and panelists waited for 30 min before tasting the next sample.  
Statistical analysis was carried out using IBM SPSS Statistics software package, version 20.0 
(SPSS Inc., Chicago, USA). One-way analysis of variance (one-way ANOVA) with post hoc 
analysis using Tukey’s HSD test, was applied. Statistical significance was estimated based on the 
p-values (p < 0.05). Regression analysis was applied in order to estimate degree of correlation 
between obtained data (Microsoft Office Excel 2007, Microsoft, Redmond, USA).  
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 Results and discussion 
Coated particles characteristics 
Particle size distribution and flow properties of coated paracetamol and caffeine samples are 
shown in Table 3. Particle size analysis revealed that fractions of fine (< 63 µm) and very large 
(> 355 µm) particles were negligible for both PAR and CA samples. The largest particle 
fractions in the case of both drugs were in the size range from 125 to 180 µm. Because particles 
greater than 350 µm can lead to unpleasant taste in mouth
11
, coated drug particles in the size 
range from 125 up to 355 µm were selected for ODT manufacture. Coated drug powder 
demonstrated significantly improved flow properties, compared to uncoated drug. The results 
obtained in this study indicate that flowability of both model drugs can be significantly improved 
by coating the particles with Eudragit
®
 E PO dispersion. This can be visualised by representative 
scanning electron micrographs of caffeine uncoated and coated particles (Figure 1), that depicted 
smoother surface of coated particles compared to uncoated caffeine particles. From the cross 
section area of coated particles difference between coated layer and caffeine crystals, as well as 
consistency of Eudragit
®
 E PO dispersion layer, can be observed. Moisture content was 0.5% for 
coated CA particles and 0.3% for coated PAR. Content of PAR and CA in coated drug samples 
was, respectively, 70.9 ± 0.3% and 69.3 ± 0.5% (which is close to theoretical value of 71.2%). 
The uniform distribution and high drug load in coated material indicate consistent coating 
procedure. High drug load in coated particles facilitates incorporation of greater amount of bitter 
drug in ODTs. To our best knowledge there are no available data in the literature about direct 
particle coating of drugs with relatively high solubility. Guhmann and coworkers applied 
diclofenac particle coating in fluidized bed as the taste-masking approach, however, additional 
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 information about process performance and coated particles characteristics has not been 
provided
11
. 
Tablet preparation 
ODTs were prepared with novel co-processed excipent Disintequik™ ODT. Published data on 
Disintequik™ ODT are still lacking, but according to manufacturer, Disintequik™ ODT is 
suitable for direct compression and production of tablets with short disintegration time and high 
breaking strength
39
.  
Tablet characteristics 
Tablet mechanical properties 
Tablet thickness, hardness, friability as well as calculated values of tablet tensile strength are 
shown in Table 4. Despite the fact that tensile strength of the investigated ODT samples showed 
high variability (1.19 up to 2.21 MPa), all values were higher than 1 MPa, which is generally 
accepted as appropriate
40
. Friability values were less than 1% for samples containing coated drug 
particles, while somewhat higher friability was observed for samples which did not contain 
Eudragit
®
 E PO. 
Disintegration testing 
Results of ODT disintegration testing are presented in Table 4. It can be observed that coating 
with Eudragit
®
 E PO affected tablet disintegration time, as tablets containing coated drug 
particles (F3 and F7) disintegrated slower in comparison to tablets containing uncoated drug (F1 
and F5) (158.1 s and 73.3 s for ODTs with coated PAR or CA, compared to 22.9 s and 30.2 s for 
ODTs with uncoated PAR or CA). Interestingly, ODTs containing coated drug particles and 
flavor (F4 and F8) exhibited markedly prolonged disintegration time and did not fulfill relevant 
pharmacopoeial requirement. Samples containing coated drug particles, as well as reference 
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 formulation (in which equivalent amount of Eudragit
®
 E PO was added) exhibited higher tensile 
strength, lower friability and longer disintegration time. Such data may result from the Eudragit
®
 
E PO binding effect.  
Dissolution testing 
Dissolution profiles of paracetamol (samples F1-F4) and caffeine (samples F5-F8), during the 
first 3 minutes, are presented in Figure 2. PAR was not detected during the first 30 s. 
Considerably slower PAR dissolution was observed from tablets containing coated drug, 
compared to tablets with uncoated drug. After three minutes, 9.5% of PAR was dissolved from 
tablets with coated drug particles (F3), compared to 92.5% of PAR dissolved from tablets 
containing uncoated drug particles (F1). In the case of tablet samples with coated drug particles, 
more than 80% of PAR was dissolved during 11 minutes from formulation F3, while for the 
same time only 19.9% of PAR was dissolved from formulation F4 which contained flavor (inset 
in Figure 2a). Slower dissolution of PAR from sample F4 can be explained by its considerably 
longer disintegration time.  
Significant differences were observed between caffeine dissolution profiles from samples 
containing uncoated drug (F5 and F6) in comparison to samples containing coated drug (F7 and 
F8). Similar to PAR release, in the first 30 s, CA concentration in the dissolution medium was 
not detectable. Caffeine dissolution from tablets containing coated particles (F7), in the first 
three minutes was three times slower compared to caffeine dissolution from tablets with 
uncoated drug particles (F5) (22.8%, compared to 66.5% of dissolved drug). 80% of caffeine was 
dissolved in less than 15 min from samples with coated drug particles (F7, F8) (inset in Figure 
2b). In the case of both model drugs, addition of flavor to the samples with uncoated drug 
particles, did not affect drug dissolution. Because of long disintegration time and slower drug 
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 dissolution, ODTs containing coated drug particles and flavor (F4 and F8) were excluded from 
further in vitro and in vivo investigation. Considering that more than 85% of drug was released 
from formulations with coated drug particles (F3 and F7) in less than 15 min, it can be assumed 
that coating with Eudragit
®
 E PO would not affect bioavailability and efficacy of the 
formulations.  
Drug dissolution in the small-volume shake-flask assembly was used as modified in vitro 
technique for taste-masking assessment which is supposed to simulate disintegration and drug 
release from ODTs in the oral cavity. Drug dissolution in small-volume shake-flask assembly 
was performed for samples F2, F3, F6 and F7, which were also selected for the in vivo study. 
The results obtained are presented in Figure 3. The profiles obtained revealed slower drug 
dissolution from formulations with coated drug particles, which is in accordance with the results 
of the compendial dissolution testing.  
In vivo study  
In the first phase of the in vivo study, bitterness values of paracetamol and caffeine were 
determined. Bitterness value obtained for PAR in individual panelist ranged from 0.9-1.3 mg/ml. 
This is in accordance with mean PAR bitterness value, determined by Albertini and coworkers 
which was 1.08 mg/ml
10
. Caffeine demonstrated higher bitterness in the individual panelist, since 
the range for bitterness value was from 0.2 to 0.3 mg/ml. Dsamou and coworkers reported 0.35 
mg/ml, as the mean bitterness value for caffeine, within the studied range from 0.07 up to 1.17 
mg/ml, including subjects hypersensitive and hyposensitive to caffeine
41
. As mentioned earlier, 
in the present study drug solution concentration which resulted in bitter taste sensation at least in 
one panelist was selected as a threshold, bitterness value. Defined values in the panelist were 0.9 
mg/ml for PAR and 0.2 mg/ml for CA. Pein and coworkers considered that taste-masking can be 
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 assumed only if the released amount of drug (in vitro), within the predefined dissolution time, 
does not exceed human perception threshold bitterness value
20
. In the present study, 
concentrations of PAR dissolved from tablets prepared with coated drug particles (F3), in the 
small-volume, shake-flask assembly, were below 0.9 mg/ml, while concentrations of PAR 
dissolved from tablets with uncoated drug particles (F2), in all the time points (excluding the 10 
s), were above 0.9 mg/ml. Dissolved amounts of CA from tablets containing uncoated drug (F6), 
in all the investigated time points, were significantly higher than defined bitterness value (0.2 
mg/ml). Concentrations of CA dissolved from tablets with coated drug (F7) were lower than 0.2 
mg/ml, except at 90 and 120 s where they were, respectively, 0.22 mg/ml and 0.25 mg/ml. Those 
values were below upper bitterness value defined in the individual panelist (0.3 mg/ml), based on 
which taste-masking can be considered successful. 
For the second phase of the in vivo study, five standard solutions with different drug 
concentrations were prepared for each model drug. The solution with lowest concentration used 
in the bitterness value determination was selected as no bitter taste solution, considering that 
none of the panelists described it as bitter. Solution concentration corresponding to the upper 
limit of the range of determined bitterness values (1.3 mg/ml for PAR and 0.3 mg/ml for CA) 
was defined as slightly bitter. In this way it was ensured that each of the panelists will recognize 
the bitter taste of that solution. The increasing concentrations of other standard solutions were 
defined in accordance with the results of preliminary trials.   
After training, panelists tasted three different formulations of each model drug, in order to 
estimate effectiveness of applied taste-masking approach. Results of the in vivo taste-masking 
assessment are shown in Table 5. Statistical analysis revealed significant difference in bitterness 
between formulations with coated drug particles (F3 and F7), compared to formulations with 
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 uncoated drug and flavor (F2 and F6), in every investigated time point (p < 0.05). According to 
lower values of the numerical scores obtained for PAR compared to those obtained for CA, it 
may be concluded that more efficient taste-masking was achieved in the case of PAR. This 
indicates that optimal amount of Eudragit
®
 E PO to achieve successful taste-masking should be 
determined for each drug specifically, taking into account drug bitterness and solubility. 
Statistical analysis revealed no significant difference in bitterness between ODTs with coated 
drug and reference drug-free ODT, 10 s after administration, while formulations with uncoated 
drug and flavor added exhibited bitter taste (numerical score ≈ 3), even at the early time point. 
The results obtained in human taste panel evaluation, indicate that addition of flavor is not a 
sufficient taste-masking approach in the case of paracetamol and caffeine ODTs. 
Modified method of standard dissolution testing can be applied as a tool for taste-masking 
effectiveness evaluation. But, correlation between in vitro dissolution data and results of in vivo 
taste assessment is still lacking. In order to estimate correlation between the in vivo and in vitro 
data, in vivo obtained numerical scores of all the investigated samples (F2, F3, F6 and F7) were 
converted to PAR or CA concentrations based on the values given in Table 2 and compared to in 
vitro drug dissolution observed in the small-volume shake-flask method. The results obtained are 
presented in Figure 4. Logarithmic relationship between in vivo PAR and CA concentration and 
in vitro drug dissolution results was observed. After logarithmic transformation of the in vitro 
determined drug concentrations, linear correlation between the in vivo and in vitro data was 
estimated, for both model drugs. Calculated values of Pearson’s coefficients were 0.997 for PAR 
and 0.970 for CA, respectively. Values for Pearson’s coefficient greater than 0.97 indicate strong 
positive correlation between in vivo and log transformed in vitro data, for both model drugs. 
Such a correlation can be used for taste-masking prediction based on in vitro drug dissolution 
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 study. The obtained results revealed that small-volume, shake-flask dissolution method, may be 
used as a surrogate for human panel taste-masking evaluation in the case of physical taste-
masking approach application. This is of great importance considering generally high variability 
of the human sense of taste, as well as the ethical and safety concerns associated with human in 
vivo studies.  
The most important characteristic of ODTs is their fast disintegration in the small amount of 
saliva. Compendial tablet disintegration test is not considered suitable for ODTs, due to large 
volumes and strong agitation
42
. Therefore, the alternative in vitro methods, which reflect the 
disintegration process in the oral cavity, have been proposed
43,44
. Mean values of in vivo ODTs 
disintegration time, reported by each volunteer, are shown in Table 4. In vivo disintegration 
times are plotted against the in vitro data obtained in compendial disintegration test, and relevant 
correlation plot is shown in Figure 5. High value of Pearson’s coefficient (r = 0.997) indicate 
strong positive linear correlation between analyzed data. Kim and coworkers obtained similar 
results, although slightly longer disintegration time of ODTs, in their case, was noticed during 
the in vivo study
45
. According to this, in vivo ODT disintegration time may be predicted based on 
the results of compendial disintegration test.   
Conclusions 
The results obtained in vitro and in vivo indicate that drug particle coating with Eudragit
®
 E PO 
can be a suitable approach for bitter taste-masking of paracetamol and caffeine anhydrous. 
Significantly slower drug dissolution from tablets with coated drug particles was observed during 
the first three minutes (which is important to prevent contact between dissolved drug and taste 
receptors and reduce bitter taste perception), while tablet disintegration and drug release from 
prepared ODTs have not been significantly impaired. Disintequik™ ODT proved to be a useful 
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 co-processed excipient in preparation of ODTs with good mechanical characteristics and 
excellent disintegration profile. Results of taste-masking assessment in a trained human taste 
panel demonstrated significant improvement in drug bitterness suppression in formulations with 
coated drug particles. Strong correlation between in vitro drug dissolution and hypothetical drug 
dissolution in oral cavity, in the predefined time points was established for both model drugs 
(Pearson’s coefficient greater than 0.97). The results obtained indicate that, in the case of 
physical taste-masking approach, small-volume, shake-flask dissolution method may be used as 
surrogate for human panel taste-masking assessment.  
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Figure captions 
Figure 1. Scanning electron micrographs of: a) uncoated caffeine particles; b) coated caffeine 
particles; c) cross-section of coated caffeine particles. 
Figure 2. Dissolution profiles of: a) paracetamol, F1-F4 formulations; b) caffeine, F5-F8 
formulations. 
Figure 3. Dissolution profiles of paracetamol (F2, F3) and caffeine ODTs (F6, F7) observed in 
the small-volume, shake-flask assembly. 
Figure 4. Correlation between the in vitro and in vivo dissolved amount of a) paracetamol; b) 
caffeine; (with estimated regression equation and coefficient of determination). 
Figure 5. Correlation between in vitro and in vivo paracetamol and caffeine ODT disintegration 
time (with estimated regression equation and coefficient of determination). 
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 Table 1. Composition of the investigated ODT formulations. Samples F1-F4 contained 
paracetamol, while samples F5-F8 contained caffeine. 
Component (%) F1 F2 F3 F4 F5 F6 F7 F8 
Paracetamol/Caffeine 25.00 25.00 - - 25.00 25.00 - - 
Coated paracetamol/caffeine - - 35.24 35.24 - - 36.06 36.06 
Flavour - 5.00 - 5.00 - 5.00 - 5.00 
Disintequik™ ODT 74.50 69.50 64.26 59.26 74.50 69.50 63.44 58.44 
Sodium stearyl fumarate 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 
 
 
Table 2. Numerical score system and description of drug aqueous solutions used for volunteers 
training. 
Numerical score/Description 
Concentration of aqueous standard solutions (mg/ml) 
Paracetamol Caffeine 
0/no bitter taste 0.5 0.1 
1/slightly bitter 1.3 0.3 
2/moderately bitter 2.1 0.6 
3/bitter 3.5 1.2 
4/very bitter 5.0 2.4 
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 Table 3. Drug particle characterization. 
 PAR Coated PAR CA Coated CA 
Flowability*
 
(g/s) 0.99 ± 0.16 8.31 ± 0.56 1.48 ± 0.01 9.44 ± 0.40 
Particle size range  %  % 
< 63 µm - 1.61 - 0.23 
63 – 125 µm - 14.65 - 2.19 
125 – 180 µm - 15.64 - 30.24 
180 – 250 µm - 57.04 - 49.62 
250 – 355 µm - 10.26 - 14.46 
> 355 µm - 0.8 - 3.26 
*Mean ± standard deviation (n = 3) 
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 Table 4. ODT characterization. 
Tablet 
properties 
F1 F2 F3 F4 F5 F6 F7 F8 
Reference 
formulation 
Tablet 
thickness
 
 
(mm) 
3.15  
 
3.20  
 
3.20  
 
3.30  
 
3.10  
 
3.15  
 
3.22  
 
3.20  
 
3.20  
 
Tablet 
hardness* 
(N) 
57.67 ± 
5.77 
48.00 ± 
5.00 
61.00 ± 
1.41 
78.33 ± 
3.05 
62.33 ± 
3.06 
54.33 ± 
1.53 
57.67 ± 
1.53 
77.33 ± 
0.58 
89.33 ± 
3.06 
Tensile 
strength*
 
 
(MPa) 
1.46 ± 
0.15 
1.19 ± 
0.12 
1.50 ± 
0.01 
1.89 ± 
0.07 
1.62 ± 
0.08 
1.47 ± 
0.05 
1.43 ± 
0.05 
1.93 ± 
0.02 
2.21 ± 
0.07 
Friability 
(%) 
2.85 2.41 0.93 0.86 2.16 1.93 1.01 0.69 1.16 
DT†, in 
vitro* 
 (s) 
22.89 ± 
1.03 
21.40 ± 
0.88 
158.10 ± 
5.22 
993.37 ± 
10.69 
30.18 ± 
1.02 
40.27 ± 
4.79 
73.31 ± 
4.82 
472.51 ± 
63.51 
172.61 ± 
6.08 
DT†, in 
vivo‡ 
 (s) 
- 
33.90 ± 
12.01 
121.20 ± 
38.11 
- - 
38.50 ± 
10.76 
63.50 ± 
19.72 
- - 
*Mean ± standard deviation (n = 6) 
†Disintegration time 
‡Mean ± standard deviation (n = 10) 
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 Table 5. Results of taste-masking evaluation. 
Mean value of bitterness score determined in volunteers  
(mean ± SD, n = 10) 
 10 s 30 s DT* DT* + 10 s 
F2 2.9 ± 1.3 3.3 ± 0.7 3.6 ± 0.5 3.2 ± 
0.6 
F3 0.4 ± 0.7 0.9 ± 0.7 1.8 ± 0.9 1.9 ± 
1 
F6 2.7 ± 1.2 3.5 ± 0.5 3.6 ± 0.5 3.5 ± 
0.5 
F7 0.9 ± 1.3 2.2 ± 1.5 2.4 ± 0.8 2.5 ± 
0.8 
Reference formulation 0 0 0 0 
*Disintegration time 
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